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ABSTRACT OF THE THESIS 
 
Comparison of Oncological Outcomes and Cost of Adjuvant Radiation versus  
Observation for Post-Radical Prostatectomy Patients 
 
By 
 
Huang-Wei Su 
 
Master of Science in Biomedical and Translational Science 
 
 University of California, Irvine, 2019 
 
Professor Thomas E. Ahlering, Chair 
 
 
 
Objective: To analyze the oncological outcomes of “at-risk” men with Prostate 
cancer (PC) following radical prostatectomy who were managed without versus with 
adjuvant radiation therapy (ART). Additionally a cost comparison will be conducted 
between radiotherapy and observation groups. 
 Patients and Methods: 1500 men who underwent robot-assisted radical 
prostatectomy (RP) and no adjuvant radiation therapy at UC Irvine constitute the 
comparator group, (Observation group) of men who had a RP for prostate cancer and 
managed without ART. Observation patients with no PSA follow-up or who had pre-
operative treatment were excluded.  All data was prospectively collected and 
retrospectively analyzed in the observation group. Two comparator groups of men who 
received ART were selected from two randomized control trials (SWOG 8794 and EORTC 
22911) and separately analyzed against the UCI observation group. Outcomes assessed in 
the analysis include Biochemical recurrence (BCR), metastasis-free survival, prostate 
cancer specific mortality (PCSM) and Overall survival. Kaplan-Meier analysis was utilized 
ix 
 
to compare outcomes with previous randomized control trials. Medicare reimbursement 
rates were used to estimate cost of secondary interventions. 
 Results: 364 patients were selected by SWOG 8794 inclusion criteria. After adjusting 
by proportion of Gleason score and pathological stage, the UCI observation cohort had non-
inferior outcomes with metastasis-free and overall survival rate than the trial. Also, 
analysis in 368 men who were qualified by EORTC 22911 inclusion criteria demonstrated 
the similar non-inferior results in overall survival and cancer-specific survival rate. Cost 
per patient in the RCTs was $26,343 for ART groups and $7,874 in the RCT control groups 
after considering primary, secondary complication treatment expenses versus UCI only 
$3,544 per patient. 
 Conclusion: Radiation-naïve patients had non-inferior oncological outcomes as 
compared to men receiving ART. The expense of ART is three to seven times higher than 
radiation-naïve men. Decision of early radiation treatment should be re-evaluated because 
of the lack of mortality benefit, side effects of radiotherapy and cost. 
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I. INTRODUCTION 
1. Background 
Prostate cancer is the most common cancer and the second leading cause of cancer 
death in men. [1] Radical prostatectomy (RP), external beam radiation therapy (EBRT), 
brachytherapy, chemotherapy, and androgen deprivation therapy (ADT) are treatment 
options for these patients. [2] One common way to manage prostate cancer is via robot-
assisted radical prostatectomy (RARP). For those patients who undergo radical 
prostatectomy, the incidence rate of biochemical recurrence (BCR) is about 15-25%. [3] 
BCR is an important outcome post-RP and is identified by prostate-specific antigen (PSA) of 
0.2 ng/mL or greater on 2 consecutive tests. [4] Since the early 1990s, adjuvant radiation 
therapy (ART) has been recommended following RP for men believed at increased risk for 
BCR due to positive surgical margins, extraprostatic disease (pathologic T3 disease) and/or 
high-grade (Gleason 8-10) disease. [5] ART is often used in these patients who have 
adverse pathological features in effort to decrease risk of recurrence. [6] In addition to ART, 
ADT or chemotherapy are often considered in conjunction for these post-operative patients.  
2. Trial review and major consensus on radiotherapy 
Based on the National Comprehensive Cancer Network (NCCN) guidelines, ART is 
advocated to post-operative patients when they have any combination of poor pathological 
characteristics (i.e. seminal vesicle invasion (SVI), extraprostatic extension (EPE), positive 
surgical margins or higher Gleason scores). [6] Three randomized control trials (RCT) of 
ART versus observation present evidence that adjuvant radiotherapy could improve PSA 
control. However, only one showed benefit on overall and prostate cancer specific survival. 
The findings of these trials are summarized in Table 1. [3, 14] 
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Table 1: Major 2 trials on post-operative adjuvant radiotherapy  
Trial Study design Conclusion 10-yr BCR-
free rates 
10-yr 
Metastasis-free 
10-yr 
Overall 
survival 
U.S. 
SWOG 
8794 
pT2 / positive 
surgical 
margins or 
pT3 
with/without 
positive 
surgical 
margin 
Benefits BCR, 
metastasis-
free and 
overall 
survival rates 
PSA relapse 
(PSA>0.4) 
ART vs. 
observation:
64% vs. 
34.9%; 
p<0.01  
ART vs. 
observation:71
% vs. 61%; 
p=0.016 
ART vs. 
observation:
74% vs. 
66%; 
p=0.023 
Europe 
EORTC 
22911 
pT2-3  
with/without 
positive 
surgical 
margin 
Benefits BCR 
; No benefit 
in 
metastasis-
free, PCSM or 
overall 
survival. 
ART vs. 
observation:
60.6% vs. 
41.4%; 
p<0.0001 
ART vs. 
observation:76.5
% vs. 71.3%; No 
significant 
ART vs. 
observation:
76.9% vs. 
80.7%; No 
significant 
 
2.1 The American Trial, SWOG 8794 
The Southwest Oncology Group (SWOG) 8794 trial recruited 425 patients with pT2 
disease with positive surgical margins or pT3 with or without positive surgical margins 
between 1988 and 1997. They then randomized their patients to ART versus observations. 
Metastasis-free and survival rate were their primary endpoints. For their results, 10-year 
metastasis-free rate was 71% in the ART group compared with 61% in observation group 
(HR=0.7; P=0.016). Also, 10-year survival rates were 74% and 66% for ART and 
observation (HR=0.72; P= 0.023). Both endpoints showed statistically significant 
improvement in the ART group but only had 1.9 years difference in overall survival and 1.8 
years difference in metastasis between two groups. Coincidentally, their adjuvant radiation 
therapy group began the trial at an average of 1.8 years older than the observation group.  
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To conclude, they found that ART decreased time to PSA progression. However, there 
was a significant 24% general complication rate in the ART group, compared to only 12% 
in the observation patients (P=0.002). For example, both rectal and urinary toxicity had 
higher chance of happening in the ART group. [3, 7-9] These findings suggest that ART does 
not come at a nominal cost to these patients. 
2.2 The European Trial, EORTC 22911 
1005 patients with pT2-3 N0 with or without positive surgical margins were included 
in the European Organization for Research and Treatment of Cancer (EORTC) 22911. Their 
primary outcome, BCR-free rate was significantly different between the ART versus 
observation group; however, they could not identify improvement on overall survival, 
distant metastasis, or prostate cancer specific mortality. Similar to evidence from the 
SWOG trial, EORTC also had a higher rate of side effects in their treatment group. According 
to the Late Radiation Morbidity Scoring Scheme of the Radiation Therapy Oncology Group, 
late side effects were measured for patients and Grade 3 toxicity incidence rates in ART and 
observation group were 4.2% and 2.6%, respectively. [3, 7, 10-11] Again, these findings 
suggest significant reduction in quality of life for patients receiving ART; in EORTC, this 
should be weighed against the lack of long-term benefit to overall survival, distant 
metastasis or prostate cancer specific mortality. 
3. Specific aims 
Because of the above two major RCTs, current guidelines promote ART for patients 
with poor pathological features (i.e. SVI, EPE, positive surgical margins or higher Gleason 
scores). They state that better PSA control could reduce risk of recurrence but there is a 
lack of evidence to support benefit to long-term metastasis and overall mortality. [12-14]  
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Despite suggestion from guidelines, ART is not often recommended by these characteristics 
alone by many clinicians for control of PSA because the disparity between the two trials. A 
key determining factor continues to be an increase in the risk of side effects such as 
gastrointestinal or genitourinary toxicity. This is an especially pertinent consideration 
since ART only had advantage on BCR rate and not on long-term survival. [15] In this 
regard, we seek to assess the effect of adjuvant radiation therapy for reducing risk of 
recurrence, metastatic progression, PCSM or overall mortality. We will then compare the 
RCT findings to a matched “at-risk” UCI-cohort of radiation-naïve patients in order to 
perform a comparison of oncological outcomes. Finally, we conduct a cost analysis of 
adjuvant radiation versus active surveillance medically related expenses. 
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II. PATIENT SELECTION AND METHODS 
1. Literature review 
SWOG 8794 and EORTC 22911 are major trials that emphasize the benefit of ART in 
slowing PSA progression. We will use their patient demographics and Kaplan-Meier 
estimates to compare oncologic outcomes with an observation cohort of radiation-naïve 
patients. Also, articles related to adverse events, side effects, and cost were also reviewed.   
2. Outcomes analysis and patient selection  
For outcomes analysis, our data were collected and recorded to an electronic 
spreadsheet under approved institutional review board protocol and in accordance with 
the Health Information Portability and Accountability At. Every patient who underwent 
RARP as primary treatment for localized prostate cancer between 2002 and 2015 were 
included (N=1500). Patients without PSA follow-up or had any pre-operative treatments 
were excluded (N=40). All patients’ information was prospectively maintained and the 
latest date of follow-up was obtained in order to calculate the median follow-up years. To 
date, we have been screened all data and formed a research database for comparison and 
analysis.  
In outcomes analysis, the observation patients group consisted of the above 1500 
patients, compared ad-hoc with previous trials. In order to test patient similarity, we 
applied each trial’s inclusion and exclusion criteria to our patient group and create the 
demographic tables. Figure 1a and 1b are the process graph for using SWOG 8794 and 
EORTC 22911 to choose patients. 
Figure 1a: Patient selection by SWOG 8794 inclusion criteria 
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Figure 1b: Patient selection by EORTC inclusion criteria 
 
 
3. Cost analysis 
The cost analysis model for estimating the variation of patient’s cost on follow-up 
treatment was modeled after Showalter and associates’ [2011] publication in Annals of 
oncology]. Figure 2 depicts the treatment schema used to estimate the expense for ART and 
no ART group in the two RCTs. Assumptions of cost were collected and listed in Table 2. 
Cost estimates for ART, salvage radiotherapy (SRT), hormonal therapy and management of 
complications were also included in the table. Rectal bleeding and urinary stricture were 
considered as major complications for post-radiation patients. Finally, Medicare 
reimbursement rates were used to assess the treatment of radiation, gastrointestinal or 
All patients underwent RARP (N=1500)
Excluded:  
1. Patients without any PSA follow-up 
2. Pre-op treatment patients
(N=40)
Patients have PSA follow-up (N=1460)
Eligible patients:
1. Clinical T1-2 prostate cancer 
2. pT2 N0 with positive surgical margins or pT3 N0 disease
(N=364)
All patients underwent RARP 
(N=1500)
Excluded:  
1. Patients without any PSA follow-up 
2. Pre-op treatment patients
(N=40)
Patients have PSA follow-up 
(N=1460)
Eligible patients:
1. Clinical T0-3 prostate cancer 
2. pT2-3 N0 disease
3. Age<76 years old
(N=368)
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genitourinary toxicity. Probabilities of side effects, SRT and hormonal therapy were 
directly obtained from the trials. [8, 10, 16, 22]  
Figure 2: Treatment schema for post-operative patient 
 
Table 2: Cost values in the treatment schema  
Cost values Value Reference 
ART $24,548 Luo et al. [23] 
SRT $16,755 Luo et al. [23] 
Rectal bleeding treatment $2,660 2010 Medicare reimbursement rates 
Urinary stricture 
treatment  
$4,648 2010 Medicare reimbursement rates 
Hormonal therapy $8,991 Krupski et al. [24] 
*The low and high values were calculated by one way sensitivity analyses 
Table 2b: Probability values in SWOG 8794 trial 
Probability SRT Rectal bleeding 
treatment 
Urinary 
stricture 
treatment 
Hormonal 
therapy 
Observation 0.33 0 0.095 0.21 
ART N/A 0.033 0.178 
 
0.1 
*N/A: Not applicable 
RP patients
No ART
No evidence of 
disease
BCR 
Salvage RT
Rectal bleeding
Urinary 
stricture
Hormonal 
therapy
ART
No BCR
Rectal bleeding
Urinary 
stricture
BCR
Hormonal 
therapy
Rectal bleeding
Urinary 
stricture
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4. Statistical Analysis 
All statistical analysis was conducted in SPSS v 14 © IBM. Age, ethnicity, pathologic 
Gleason score, PSA data and pathological features (i.e. SVI, EPE, positive surgical margins or 
high-risk Gleason scores) were displayed in demographic tables. Continuous variables 
were reported using mean; categorical variables were reported with count and proportions. 
Rates of each adverse pathological feature, overall mortality, metastasis-free survival and 
PCSM were calculated and compared between NED and BCR groups. Kaplan-Meier models 
were built to compare 5 year rate of BCR-free, overall mortality, metastasis-free rate, and 
PCSM between each of the two randomized control trials and our cohort of observation / 
radiation-naïve patients. In addition, we adjusted our patients by both trials’ proportion of 
Gleason score and pathological stage in order to have more similarity on patient’s 
progression. Chi-square test was utilized to compare the proportion between RCTs and UCI 
patients before and after adjustment. [8, 16] 
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III. RESULTS 
1. Baseline characteristics  
1.1 The American Trial, SWOG 8794 
364 patients in our clinic were selected by SWOG 8794 criteria in Table 3.  Compared to 
the trial cohort, a few key differences should be noted. First, because patients who had 
treatments before surgery was one of our exclusion criteria, we did not have patients with 
pre-operative hormonal therapy. Second, most of our patient’s ethnicity was white. Third, 
regarding pathological features, only 3.6% of our patients had extracapsular extension with 
seminal vesicle invasion or positive surgical margin with seminal vesicle invasion. Due to 
these differences, the SWOG trial had disproportionate rate of Grade 2-6 and 8-10 favoring 
ART group. This difference would favorably impact Metastasis-Free survival. Finally, for 
patient’s pre-op and post-op PSA, UC Irvine’s observation group had lower mean value.  
Table 3: Baseline characteristics for SWOG 8794 and our patients 
  Observation 
Adjuvant 
Radiation 
UCI Patient 
(Unadjusted) 
UCI patient 
(Adjusted) 
No. subjects 211 214 364 80 
Median age 65.8 64.1 63 62 
Median yrs follow-up 12.5 12.7 5.4 6.9 
% Pre-op hormonal therapy use:  
    Yes 8 9 0 0 
    No 92 91 100 100 
% Ethnicity  
    White 67 72 98.1 95 
    Black 20 19 0.8 2.5 
    Other 13 9 1.1 2.5 
% Pathological extent of 
disease: 
 
    Extracapsular extension or 
positive margin 68 67 86.5 
 
66 
    Seminal vesicle invasion 11 10 9.9 18 
10 
 
    Both 21 23 3.6 16 
No. with Gleason score data 159 166 364 80 
% Gleason score:  
    2–6 46 57 11 50 
    7 38 34 71.7 33 
    8–10 16 9 17.3 17 
No. with pre-op PSA data 154 148 364 80 
% Pre-op PSA:  
    Less than 10 ng/ml 52 47 80.2 76.3 
    10 ng/ml or Greater 48 53 19.8 23.7 
No. with post-op PSA data 186 190 364 80 
% Post-op PSA:  
    Less than 0.2 ng/ml 68 65 94.2 92.5 
    0.2 ng/ml or Greater 32 35 5.8 7.5 
 
1.2 The European Trial, EORTC 22911 
EORTC had no internal demographic issues. Table 4 compares our patients with that of 
the EORTC trial. Again, key differences to note are as follows. First, the median age in our 
observation patient cohort was 63 and we did not have patients who had WHO 
performance status higher than 0. WHO performance grade 0 was defined that patient 
could perform all normal activity without restriction. [17] Second, UC Irvine had less 
aggressive pathology when compared to the EORTC trial, based on percentage difference in 
high Gleason score group (8-10) 
Table 4: Baseline characteristics for EORTC 22911 and our patients 
  
Wait and 
See(N=503) 
Irradiation(n=50
2) 
Total(n=1005
) 
UCI(N=368) 
(Unadjusted) 
UCI 
(N=252) 
(Adjusted) 
Median age 
(years) 65 65 65 63 
 
63 
WHO 
performance 
status* 
 
   0 473(94%) 471(93.8%) 944(93.9%) 368(100%) 252(100%) 
   1 29(5.8%) 26(5.2%) 55(5.5%) 0(0%) 0(0%) 
11 
 
   2 1(0.2%) 2(0.4%) 3(0.3%) 0(0%) 0(0%) 
   Missing 0 3(0.6%) 3(0.3%) 0(0%) 0(0%) 
Clinical tumor 
stage         
 
   cT0 2(0.4%) 4(0.8%) 6(0.6%) 0(0%) 0(0%) 
   cT1 84(16.7%) 87(17.3%) 171(17%) 204(55.4%) 142(56.3%) 
   cT2 337(67%) 316(62.9%) 653(65%) 141(38.3%) 91(36.1%) 
   cT3 80(15.9%) 94(18.7%) 174(17.3%) 23(6.3%) 19(7.5%) 
   cTx 0(0%) 1(0.2%) 1(0.1%) 0(0%) 0(0%) 
Clinical nodal 
status 
 
   cN0 494(98.2%) 486(96.8%) 980(97.5%) 368(100%) 252(100%) 
   cNx 9(1.8%) 16(3.2%) 25(2.5%) 0(0%) 0(0%) 
Metastatic 
status         
 
   M0 500(99.4%) 494(98.4%) 994(98.9%) 363(98.6%) 246(97.6%) 
   M1 0 1(0.2%) 1(0.1%) 5(1.4%) 6(2.4%) 
   Mx 3(0.6%) 7(1.4%) 10(1%) 0(0%) 0(0%) 
Median PSA 
before 
surgery 
(μg/L) 12.5 12.3 12.4 6.2 
 
 
 
6.5 
PSA after 
surgery 
before 
irradiation         
 
   ≤0·2 μg/L 345(68.6%) 353(70.3%) 698(69.5%) 353(96%) 239(94.8%) 
   >0·2 μg/L 157(31.2%) 144(28.7%) 301(29.9%) 15(4%) 13(5.2%) 
   Unknown 1(0.2%) 5(1%) 6(0.6%) 0(0%) 0(0%) 
Pathological 
nodal status         
 
   pN0 501(99.6%) 495(98.6%) 996(99.1%) 209(56.8%) 148(58.7%) 
   pN+ 0 2(0.4%) 2(0.2%) 0(0%) 0(0%) 
   pNx 2(0.4%) 2(0.4%) 4(0.4%) 159(43.2%) 104(41.3%) 
   Missing 0 3(0.6%) 3(0.3%) 0(0%) 0(0%) 
WHO 
histopathologi
cal grade**         
 
   G1 57(11.3%) 69(13.7%) 126(12.5%) 39(10.6%) 35(14%) 
   G2 327(65%) 303(60.4%) 630(62.7%) 266(72.3%) 154(61%) 
   G3 116(23.1%) 122(24.3%) 238(23.7%) 63(17.1%) 63(25%) 
   Gx 3(0.6%) 5(1.0%) 8(0.8%) 0(0%) 0(0%) 
   Missing 0 3(0.6%) 3(0.3%) 0(0%) 0(0%) 
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Pathological T 
stage         
 
   pT2(R1) 79(15.7%) 84(16.7%) 163(16.2%) 52(14.1%) 52(20%) 
   pT3a 296(58.8%) 288(57.4%) 584(58.1%) 267(72.6%) 151(60%) 
   pT3b 128(25.4%) 128(25.5%) 256(25.5%) 49(13.3%) 49(20%) 
   Ineligible 0 2(0.4%) 2(0.2%) 0(0%) 0(0%) 
Pathological 
risk factors          
   Capsule 
perforation 397(78.9%) 377(75.1%) 774(77%) 267(72.6%) 
 
151(59.9%) 
   Seminal 
vesicle 
invasion 128(25.4%) 128(25.5%) 256(25.5%) 48(13%) 
 
 
49(19.4%) 
   Positive 
surgical 
margin 317(63%) 312(62.2%) 629(62.6%) 137(37.2%) 
 
 
100(39.7%)
) 
*WHO performance status: 0 (Able to perform all normal activity without restriction), 1 
(Restricted in physically strenuous activity but ambulatory and able to carry out light 
work), 2 (Ambulatory and capable of all self-care but unable to carry out any work; up and 
about more than 50% of waking hours.  
**WHO histopathological grade: G1 (Gleason score 2-6), G2 (Gleason score 7), G3 (Gleason 
score 8-10) [17] 
 
2. Comparison with previous RCTs (SWOG 8794 and EORTC 22911) 
2.1 The American Trial, SWOG 8794 
In Table 5a, 364 (25%) patients were indicated to undergo ART. BCR occurred in 120 
(33%) patients. Median follow-up data was 5.2 years for the patients and 83% had follow-
up PSA over 2 years. We only had 5 patients who underwent ART and 38 patients who 
underwent SRT. OM was similar between NED and BCR group: 18 (49%) and 19 (51%), 
respectively. In comparison to survival rate with previous trials, we had lower OM (2.5%) 
and PCSM (0.7%) rates. After adjusting by proportion of Gleason score and pathological 
stage in the trial, we used Kaplan-Meier to estimate the 5 years metastasis-free and 
survival rate graph in figure 3.  
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Table 6a was the unadjusted and adjusted clinical outcomes compared between the 
trial and our UC Irvine cohort of observation patients. For status of metastasis, besides the 
patients who had metastasis in bone scan, we also assumed patients who died of prostate 
cancer within 7 years of the radical prostatectomy had metastasized. Even with adjustment 
of our patient cohort to match the proportion of high-risk Gleason score and high-volume 
pathological stage in the trial, we had a 98% metastasis-free rate [Unadjusted and adjusted 
p-value<0.0001]. Comparison of proportion on unadjusted and adjusted metastasis-free 
and overall survival rates were calculated in table 6a, 7a and 7b.  
Table 5a: Patient Pathological Features meeting SWOG 8794 inclusion criteria 
N=1460 
Total 
patients 
Tx per 
SWOG 
pT3b pT3 (+)SM 
Tx w/ 
ART 
Tx w/ 
SRT 
Mortality PCSM 
Total 1460 364 51 261 52 5 38 37 10 
% of 
1460 
N/A 24.93% 3.49% 17.88% 3.56% 0.34% 2.60% 2.53% 
0.68
% 
NED 1141 244 20 183 41 2 0 18 0 
% of 
total 
78.15% 67.03% 39.22% 70.11% 78.85% 40% 0% 48.65% 0% 
BCR 319 120 31 78 11 3 38 19 10 
% of 
total 
21.85% 32.97% 60.78% 29.89% 21.15% 60% 100% 51.35% 100% 
*N/A: Not applicable 
Figure 3: Adjusted Kaplan-Meier of our patient cohort, per SWOG 8794 inclusion criteria 
(Metastasis-free and Overall survival rate) 
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Table 6a: Outcomes comparison with SWOG 8794 (Metastasis-free and Overall survival rate) 
 Table 7a: Summary table on comparison of proportion (Unadjusted Metastasis-free and 
Overall survival rate) 
 5 yrs Metastasis-free rate 5 yrs Overall Survival 
SWOG     
   ART group 85%  89%  
   No ART group  81%  88% 
UCI     
   Unadjusted 98% 98% 94% 94% 
Unadjusted p <0.0001 <0.0001 0.013 0.003 
 
Table 7b: Summary table on comparison of proportion (Adjusted Metastasis-free and Overall 
survival rate) 
 SWOG 8794 Our patients 
 ART group No ART group Unadjusted Adjusted 
Inclusion criteria  RP patients with Clinical T1–2 
prostate cancer  
 Pathological T3 disease with 
at least one of the adverse 
features 
 
5 years Metastasis-free 
rate 
85% 81% 98% 98% 
5 years Survival rate 89% 88% 94% 96% 
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 5 yrs Metastasis-free rate 5 yrs Overall Survival 
SWOG     
   ART group 85%  89%  
   No ART group  81%  88% 
UCI     
   Adjusted 98% 98% 96% 96% 
Adjusted p <0.0001 <0.0001 0.0003 <0.0001 
2.2 The European Trial, EORTC 22911 
368 (25%) patients from our observation cohort fell within EORTC inclusion criteria 
and were compared to the EORTC trial. All distributions for each variable in table 5b were 
almost identical to the SWOG trial. In our patients within 5.3 median follow-up years, 124 
(34%) patients had BCR and 7 (0.5%) of them went through ART. Only 38 (2.6%) patients 
died in total and both No evidence of disease (NED) and BCR groups had equal OM. Figure 
3b showed that BCR-free, survival and PCSM-survival graphs were made by Kaplan-Meier 
and tested our result in 5 years. We also adjusted our patient cohort by pathologic Gleason 
score and pathological stage before applying survival analysis.  
As depicted in table 6b, we had a lower percentage of BCR-free rate (67%) compared 
with ART group (79%) in the trial. However, we still had high survival (93%) and PCSM-
survival rate (97%). In table 8a and 8b, EORTC trial had significant difference with UCI in 
unadjusted and adjusted BCR-free rate. However, there were no differences between trial 
and UCI in overall survival and cancer-specific survival rate. 
Table 5b: Patient Pathological Features meeting EORTC 22911 inclusion criteria 
N=1460 
Total 
patients 
Tx per 
EORTC 
pT3b pT3 (+)SM 
Tx w/ 
ART 
Tx w/ 
SRT 
Mortality PCSM 
Total 1460 368 49 267 52 7 43 38 13 
% of 
1460 
N/A 25.21% 3.36% 18.29% 3.56% 0.48% 2.95% 2.60% 0.89% 
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NED 1141 244 20 183 41 2 0 19 0 
% of 
total 
78.15% 66.30% 40.82% 68.54% 78.85% 28.57% 0% 50% 0% 
BCR 319 124 29 84 11 5 43 19 13 
% of 
total 
21.85% 33.70% 59.18% 31.46% 21.15% 71.43% 100% 50% 100% 
*N/A: Not applicable 
Figure 3b: Kaplan-Meier of our patient cohort, per EORTC 22911 inclusion criteria (BCR-free, 
Overall survival and Cancer-specific survival) 
 
 
Table 6b: Outcomes comparison with EORTC 22911 (BCR-free, Overall survival and Cancer-
specific survival) 
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 EORTC 22911 Our patients 
 ART group No ART group Unadjusted Adjusted 
Inclusion criteria  Prostate cancer clinical stage  T0–3 
N0 M0 
 Pathological stage pT2–3 N0, with 
at least one of the adverse features 
 
5 years BCR-free 
rate 
79% 54% 69% 67% 
5 years Survival 
rate 
91% 92% 94% 93% 
5 years PCSM-
survival rate 
98% 97% 98% 97% 
Table 8a: Summary table on comparison of proportion (Unadjusted BCR-free, Overall survival 
and Cancer-specific survival) 
 5 yrs BCR-free 5 yrs Overall Survival 5 yrs Cancer Survival 
EORTC       
   ART group 79%  91%  98%  
   No ART group  54%  92%  97% 
UCI       
   Unadjusted 69% 69% 94% 94% 98% 98% 
Unadjusted p 0.0001 <0.0001 0.07 0.21 1 0.3 
 
Table 8b: Summary table on comparison of proportion (Adjusted BCR-free, Overall survival 
and Cancer-specific survival) 
 5 yrs BCR-free 5 yrs Overall Survival 5 yrs Cancer Survival 
EORTC       
   ART group 79%  91%  98%  
   No ART 
group 
 54%  92%  97% 
UCI       
   Adjusted 67% 67% 93% 93% 97% 97% 
Adjusted p <0.0001 <0.0001 0.24 0.54 0.27 1 
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3. Cost estimation for patients 
In Table 9, SWOG trial patients in no ART group had urinary complication, SRT and 
hormonal therapy cost. The observation group had no patient experiencing rectal 
complication. ART, hormonal therapy, rectal bleeding and urinary toxicities management 
were included in treatment group. For internal estimation, ART and no ART patients spent 
$26,343 and $7,874 per patient, respectively. Most of our patients did not go through ART 
and therefore cost of secondary intervention in our clinic was about $3,544 per patient. 
Table 9: Cost comparison with SWOG 8794 and UC Irvine observation patients 
 SWOG 8794 Our patient group 
(N=364)  No ART (N=211) ART (N=214) 
ART cost 0 $24,548 per patients × 
214 patients in trials  
$24,548 per patients × 
5 patients in our clinic  
Complicat
ion cost 
Urinary stricture cost 
&4,648 × 20 patients  
a. Rectal bleeding cost 
$2,660 × 7 patients 
b. Urinary stricture cost 
$4,648 × 38 patients  
0  
Treatmen
t cost 
a. RT cost =$16,755 × 
70 patients 
b. HT cost =$8,991 × 
44 patients  
HT cost =$8,991 × 21 
patients  
a. RT cost = $16,755 × 
38 patients  
b. HT cost =$8,991 × 59 
patients  
Total Cost  $1,661,414 $5,637,327 $1,289,899 
Cost per 
patient  
$7,874 $26,343 $3,544 
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IV. DISCUSSION 
1. Interpretation for the results 
First, we used SWOG 8794 and EORTC 22911 inclusion criteria in our clinic to examine 
the resemblance of patient’s formation. After selecting patients by trial’s criteria, we 
counted the number of patients with BCR, OM and PCSM in tables. Only one third of 
patients had BCR and a very small proportion in OM and PCSM. Because of the difference of 
distribution in high risk group, we adjusted our patients by Gleason score and pathological 
stage before analyzing the outcomes. As a result, Kaplan-Meier graphs presented high 
survival rate for every outcomes, with the exception of the BCR-free rate.  
In cost assessment, we did not separate our patient into treatment and control 
group when we estimated our cost. The reason why we kept it as one group was that only 5 
patients underwent ART.  If clinician or health care system wants to support ART, they 
would have to reduce half of ART cost for each patient or improve their survival rate 
outcomes. To sum up, our analysis shoes that both ART and observation patients have 
similar long-term clinical outcomes but had a huge difference on medical expense. 
2. Radiotherapy timing and side effects 
Because of the limited effect on oncological outcomes, radiotherapy timing is a 
controversial issue. Fossati and colleagues recruited 510 pT3 N0 post-operative patients. 
They separated patients to ART versus observation followed by SRT and clinical outcomes 
were metastasis-free rate and OM. Within 8 years follow-up, there was no significant 
difference for outcomes between groups. Therefore, SRT may reduce the overtreatment 
effect on adjuvant radiotherapy. [18] Also, Wallis and associates developed a decision 
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analysis model for ART against SRT. In their conclusion, they found the SRT group to have 
better quality-adjusted life expectancy than the ART group. [19] Even further, the recovery 
rate of erectile function and urinary function were evaluated for post-RP patients with or 
without radiotherapy by Zaffuto and associates. They also tested the outcomes with 
different radiotherapy timing in the adjuvant versus salvage setting. For 3 years follow-up 
on functional outcomes of erectile function and urinary continence, there were significant 
difference between SRT, ART and no radiation group: SRT had better maintenance of 
outcomes compared than ART. Their results proved that late post-operative radiotherapy 
timing with indication by BCR would provide improved functional outcomes, when 
compared to proliferative radiation based only on adverse pathological characteristics. [20] 
Another question is the side effects and quality of life issues associated with 
radiotherapy. Gastrointestinal toxicity, genitourinary toxicity and sexual dysfunction could 
affect post-RP radiotherapy patient’s life quality [30]. Of note, complication rates were 
higher in radiation group in both the SWOG and EORTC trial. [8, 10] Furthermore, 
Sineshaw et al. found that declining use of radiotherapy in their research, possible 
suggesting that clinicians may be increasingly concerned about side effects and insufficient 
evidence proving survival benefit. [21]  
3. Effect on current guidelines 
ART is suggested by current guidelines by the National Comprehensive Cancer Network, 
American Urological Association, and European Association of Urology [6, 30, 31] based on 
the benefit to PSA progression. [19] However, not only the advantage of ART on PSA should 
be weighed but also the possibility of side effects and quality of life influence has to be 
informed. [22] While two large-scale randomized control trials were focused on BCR-free 
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rate, neither of them could prove the achievement of benefit towards OM or PCSM. Trock 
and his research team tested prostate cancer-specific survival in SRT, no salvage treatment 
and SRT with hormonal therapy. They demonstrated disease-specific survival rate 
improvement on patients with SRT but the salvage treatment had to be given within 2 
years of indication by BCR and PSA doubling time less than 6 months. [25] Our results and 
this article provide the suggestion that SRT may have similar or even better clinical and 
economic outcomes instead of ART. Regardless, after considering the toxicities, cost, and 
potential overtreatment via adjuvant radiation therapy, it appears that current guideline 
recommendations should be revised to a more conservative approach.  
4. Limitation 
The current study conclusions should be interpreted within the context of study design. 
First, our retrospective data was collected within 14 years post-radical prostatectomy, but 
we just had median follow-up 5.4 years. We kept contacting patients to obtain their 
information; however, some patients declined tracking regularly or did not follow-up with 
our clinic. However, 732 out of 1460 patients had follow-up beyond 5 years post-radical 
prostatectomy and it is well-known that the majority of recurrences occur within the first 
five years of surgery [32]. While follow-up can be continued to match randomized control 
trial’s 10-year follow-up period, it is likely that the estimation of oncological outcomes in 
our study matches well with 10-year outcomes.  
Second, we could not directly compare ART and observation group when we tried to 
analyze outcomes in our own data. This is largely due to the fact that adjuvant radiation 
therapy is not routinely prescribed at our institution. As such, we conducted a oncological 
outcomes analysis, finding that all comparisons were not statistical significantly different 
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between groups. In addition, every covariate, such as age, PSA, pathological T stage and risk 
factors, should be considered as a covariate when comparing oncological outcomes. To 
address this concern, we performed adjusted analysis and proportionately matched our 
patient cohorts to the demographics of the two randomized control trials. This analysis 
yielded consistent results.   
 Lastly, we can’t have a conclusive evidence that if adjuvant therapy can completely 
remove from guidelines. Even though we did the patient’s risk adjustment and get 
convincible data, we still need the large size and similar pathology of patient group to 
enhance our argument. Also, we don’t have an ability to generalize our results on study 
population because UCI clinic patient’s composition was different in many respects such as 
ethnic majority, education level and economic status.  
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V. FUTURE DIRECTION 
In terms of future direction, we may also apply same analysis process on SRT and ART 
or observation group to test the clinical outcomes such as BCR, OM and PCSM. After the 
analysis, we will try to develop a consensus regarding the timing of post-operative 
radiotherapy. In addition to the two randomized control trials presented in this work, 
RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery) 
and RTOG 0534 (Radiation Therapy Oncology Group) are RCTs of SRT with or without ADT. 
Both trials will help in examining the effect of supplemental hormonal therapy. [27] 
Generally, since many researchers noticed that ART only have benefit on BCR-free rate, we 
are advocating the need to pay more attention to OM and PCSM. In addition to oncologic 
benefit, however, adverse events and side effects of radiotherapy should also be considered 
as important influence for patients. Three major RCTs give the recommendation on ART, 
but only the German trial used inclusion of criteria on patients with undetectable post-
operative PSA. The others did not have specific requirements regarding post-surgical PSA. 
Even though they all state the PSA had better control after ART, the variety of trial’s 
analysis methods could not  provide support to radiation effect on BCR-free rate. In the 
future, we should design more detailed classification and analysis models to test the effect 
on radiotherapy after consulting with multidisciplinary experts. [26, 27] 
For the limitation about comparing directly between groups, we will seek to develop 
radiation and observation group from the Surveillance, Epidemiology, and End Results 
(SEER) program. It can help us to build similar pathology for both groups. 
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VI. CONCLUSION 
Radiotherapy after RP is suggested to improve clinical progression. However, The 
American, European and German trials are only advantageous in regards to PSA – 
outcomes of OM, metastasis-free survival, and prostate cancer survival are questionable in 
these studies. To further elucidate this effect, we demonstrate an oncological outcomes 
analysis by comparison between major RCTs and an internal cohort of radiation-naïve, 
observation patients. As a result, OM and PCSM in the trial’s radiation group are non-
inferior to our control group. Even further, it should be noted that only one-third of 
patients ever meet BCR.  
In addition to oncologic outcomes, cost is another problem derived from overtreating 
patients without indication for radiation therapy. Treating patients who may not have BCR 
after surgery will bring about unnecessary expense and side effects. Even further, the 
reduction of cost can also take off some burden from the overall health care system. Since 
the current study found insufficient support for the clinical outcomes and excessive 
treatment cost, we advise to inform patients about both the advantage and disadvantage of 
adjuvant radiotherapy.  
In summary, decision of early radiation treatment should be re-evaluated because of 
the lack of mortality benefit, disadvantage of radiotherapy and the cost.  
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